Dec 11, 2025 07:02AM
Dec 11, 2025 07:00AM
Nov 12, 2025 07:00AM
Aug 13, 2025 08:00AM
Mar 27, 2025 07:00AM
Jan 28, 2025 07:00AM
Apr 14, 2022 07:00AM BeyondSpring Announces Fourth Quarter and Year End 2021 Financial Results and Provides a Corporate Update
Jan 11, 2022 04:06PM
Jan 11, 2022 04:05PM
Dec 30, 2021 08:02AM
Dec 30, 2021 08:00AM
Dec 10, 2021 08:00AM
Dec 1, 2021 09:32AM
Dec 1, 2021 08:01AM BeyondSpring (BYSI) Receives CRL from the FDA for Plinabulin NDA for Prevention of Chemotherapy-Induced Neutropenia
Dec 1, 2021 08:00AM
Nov 30, 2021 11:08AM
Nov 29, 2021 11:29AM
Nov 24, 2021 05:09AM
Nov 19, 2021 04:04AM
Nov 18, 2021 04:18AM
Nov 17, 2021 02:05PM BeyondSpring (BYSI) call put ratio 1 call to 3.6 puts into PDUFA
Nov 11, 2021 04:26AM
Nov 10, 2021 04:57AM
Oct 21, 2021 07:00AM
Oct 20, 2021 07:00AM
Oct 18, 2021 05:16AM
Sep 20, 2021 07:32AM
Sep 20, 2021 07:30AM BeyondSpring Pharmaceuticals Announces Positive Final Phase 3 DUBLIN-3 Data with the Plinabulin/Docetaxel Combination versus Docetaxel Alone in 2nd/3rd Line Non-Small Cell Lung Cancer Patients with EG
Sep 16, 2021 07:04AM
Sep 16, 2021 07:00AM
Sep 9, 2021 07:00AM
Aug 31, 2021 07:03AM
Aug 31, 2021 07:00AM
Aug 26, 2021 07:11AM
Aug 26, 2021 07:00AM BeyondSpring Announces Exclusive Commercialization and Co-development Agreement with Jiangsu Hengrui Pharmaceuticals for Plinabulin in Greater China
Aug 10, 2021 08:00AM
Aug 4, 2021 07:02AM
Aug 4, 2021 07:00AM
Jul 14, 2021 07:35AM
Jul 14, 2021 07:30AM
Jun 17, 2021 04:00PM
Jun 17, 2021 06:52AM H.C. Wainwright Reiterates Neutral Rating on BeyondSpring Inc. (BYSI)
Jun 16, 2021 08:00AM
Jun 10, 2021 07:11AM
Jun 10, 2021 07:00AM
Jun 8, 2021 07:09AM
Jun 8, 2021 07:00AM
Jun 7, 2021 07:05AM
Jun 7, 2021 07:00AM BeyondSpring Announces Three Presentations Highlighting Positive Clinical Outcome Data from the Phase 3 Program of Plinabulin in Combination with Pegfilgrastim for the Prevention of Chemotherapy-Induc
Jun 4, 2021 07:00AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All